Font: Financial Modeling Prep • Apr 07, 2026
(NASDAQ:NEOG) is preparing to release its third-quarter earnings on April 9, 2026. Known for its food and animal safety products, Neogen operates in a competitive market alongside companies like Zoetis. Analysts expect earnings per share (EPS) to be $0.04, a significant drop from last year's $0.10.
Revenue projections for Neogen are around $204.5 million, slightly below the $204.62 million anticipated by analysts. This marks a 7.5% decrease from the previous year's $220.98 million. Such declines can impact investor sentiment and stock performance.
The recent sale of Neogen's Genomics business to Zoetis led to a 1.6% increase in share price, closing at $9.56. This strategic move might influence future earnings and market positioning. Piper Sandler's David Westenberg maintained a Neutral rating, raising the price target to $10.
Neogen's financial health shows a debt-to-equity ratio of 0.38, indicating moderate debt levels. Its current ratio of 3.91 reflects strong liquidity, suggesting the company can comfortably meet short-term obligations. These metrics are crucial for assessing financial stability.
The upcoming earnings report is pivotal. If Neogen surpasses expectations, the stock could rise. However, missing targets might lead to a decline. Management's insights during the earnings call will be key in shaping future expectations and stock performance.
|
QNCX§>
Quince Therapeutics, Inc.
|
$0.19
17.12%
|
|
JEM§>
707 Cayman Holdings Limited Ordinary Shares
|
$0.23
107.91%
|
|
OMEX§>
Odyssey Marine Exploration, Inc.
|
$1.32
58.75%
|
|
UCAR§>
U Power Limited
|
$1.44
161.15%
|
|
GPUS§>
Hyperscale Data, Inc.
|
$0.15
4.77%
|
|
INHD§>
Inno Holdings Inc.
|
$0.30
-22.72%
|
|
INTC§>
Intel Corporation
|
$58.43
10.43%
|
|
AIXI§>
Xiao-I Corporation
|
$1.48
-24.09%
|
|
VRAX§>
Virax Biolabs Group Limited
|
$0.15
7.36%
|
|
TSLL§>
Direxion Daily TSLA Bull 2X ETF
|
$10.23
-2.48%
|